ActoBio Therapeutics

2:15 PM - 2:30 PM, Monday, June 3, 2019 ・ Theater 2
ActoBio Therapeutics is pioneering a new class of microbe-based ActoBiotics biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The ActoBiotics platform produces biologics through oral or local administration with treatment applications across many diseases, including oral, gastrointestinal, and autoimmune/allergic disorders. This approach is being developed to provide safer and more efficacious treatments than injectable biologicals. ActoBio Therapeutics has a strong R&D pipeline with the latest stage candidate in Phase IIb and an extensive portfolio of candidates ready for clinical development across a number of potential indications. For further information and updates please visit us at www.actobio.com.
Ticker:
Not Provided.
Exchange:
Not Provided.
Company Type:
Company Website:
Company HQ State:
Not Provided.
Company HQ Country:
Belgium
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
AG013
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided.
Speaker
photo
CEO
ActoBio Therapeutics